TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06045572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VTM examination and breast biopsy
Description: VTM examination performed by a radiologist, at the MART (Metabolic Activity in Real-Time) station, using the SaMD Mart 2.0, according to the inspection protocol to identify breast alterations and/or suspicious images to be biopsied for validation by genetic tests and histology / immunohistochemistry.
Study: NCT05303675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and training
Description: Preoperative: An introductory information form will be filled out, and a lymphedema self-care and exercise booklet will be given.~Postoperative: Patients will be applied Progressive Upper Limb Exercises and Muscle Relaxation Training (PULE-MRT), lymphedema upper extremity circumference measurement, and symptom alert model until discharge, and Muscle Relaxation Training will continue until discharge.~Post-Discharge: They will be asked to record a diary at home. PULE-MRT will continue until day 15. The 15-day exercise program will continue for up to 3 months. Follow-up will be made by telephone according to the symptom alert model at the 1st, 2nd, and 3rd months, and at the end of the 3rd month, the breast cancer-related lymphedema self-care scale will be administered.
Study: NCT05879263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INTERMITTENT ENTERAL NUTRITITION (IEN)
Description: Administration of Enteral Nutriton (EN) by nasogastric tube in 4 bolus (24h): Duration of the infusion 1hour each shot, using an infusion pump.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTINUOS ENTERAL NUTRITITION (CEN)
Description: Administration of Enteral Nutriton (EN) by nasogastric tube during 24 hours, using an infusion pump.
Study: NCT04976153

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aSMDC
Description: Autologous Muscle Derived Cells for injection into the external anal sphincter

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control is the vehicle solution used for the study product
Study: NCT05136651

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: OurRelationship
Description: The OurRelationship Program is an online adaptation of Integrative Behavioral Couple Therapy (IBCT). It consists of 3 modules that couples complete over the course of 6-8 weeks. Couples also receive a 30-minute coaching appointment following completion of each module.
Study: NCT05247502

Intervention type: BIOLOGICAL
Intervention: Data observation
Description: At the time of participant inclusion in the study, demographic data and a baseline serum creatinine measurement will be collected. During the patient's ICU stay, the occurrence and duration of any AKI episode will be recorded. Data related to diagnostic examinations of these AKI episodes will also be collected in accordance with practices guidelines. Data related to AKI monitoring will also be collected, including serum creatinine and urea daily follow-up measurements, diuresis, and nephrotoxic use. The patient's need for extrarenal epuration or use of catecholamines will also be recorded. In the 3-month and 12-month.

Intervention type: BIOLOGICAL
Intervention: Data observation
Description: At the time of participant inclusion in the study, demographic data and a baseline serum creatinine measurement will be collected. During the patient's ICU stay, the occurrence and duration of any AKI episode will be recorded. Data related to diagnostic examinations of these AKI episodes will also be collected in accordance with practices guidelines. Data related to AKI monitoring will also be collected, including serum creatinine and urea daily follow-up measurements, diuresis, and nephrotoxic use. The patient's need for extrarenal epuration or use of catecholamines will also be recorded. In the 3-month and 12-month.
Study: NCT05182515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange
Description: Plasma exchange techniques reported in COVID-19 vary from study to study. No consensus exists on the use of a specific technique.~The use of a central venous catheter will be left to the discretion of investigators. If so, central venous catheter will be inserted through the internal jugular or femoral route under ultrasound control by a trained operator. After radiographic control of the position of the catheter and the absence of complications in the placement of the catheter, plasma exchanges will be carried out.~Three plasma exchanges of 1.5 plasma volume will be carried out every 48 hours on D1, D3 and D5. Plasma volume will be assessed by this equation VP = (1-Hct)x70xweight Body(measured). The substitution volume will be 5% albumin as first intervention. The use of a hemofiltration or centrifugation technique will be left to the discretion of each center.
Study: NCT05987670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-stethoscope
Description: Clinicians at practices in the intervention arm will be provided with one session of in-person training in use of the AI-stethoscope within 2 weeks of randomisation, including~1. Delivery and setup~2. Smartphone app installation and login~3. Pairing of all clinician smartphones with all AI-stethoscopes in the same practice~4. Demo of patient examination The AI-stethoscope will be used within its CE/UKCA-marked intended purpose. The clinical guidelines for use have been agreed by the NHS North West London Integrated Care System and Betsi Cadwaladr University Health Board Cardiovascular Executive Groups. Patients will be examined with the AI-stethoscope in accordance with these guidelines, and/or where stethoscope examination is deemed clinically appropriate. Patients will provide verbal consent for examination with the AI-stethoscope as per any physical examination performed by healthcare professionals for direct care, in accordance with UK law and General Medical Council guidelines.
Study: NCT05247502

Intervention type: BIOLOGICAL
Intervention: Data observation
Description: At the time of participant inclusion in the study, demographic data and a baseline serum creatinine measurement will be collected. During the patient's ICU stay, the occurrence and duration of any AKI episode will be recorded. Data related to diagnostic examinations of these AKI episodes will also be collected in accordance with practices guidelines. Data related to AKI monitoring will also be collected, including serum creatinine and urea daily follow-up measurements, diuresis, and nephrotoxic use. The patient's need for extrarenal epuration or use of catecholamines will also be recorded. In the 3-month and 12-month.
Study: NCT05620914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab deruxtecan
Description: Patritumab deruxtecan (HER3-DXd) will be administered IV 5.6 mg/kg as a single dose 1-3 days prior to planned craniotomy and resection of brain metastasis
Study: NCT06479005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oura Ring
Description: The Oura ring will remotely monitor the patients vitals at home continuously
Study: NCT05118204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BUP microdose induction
Description: Participants will be started on a 5-day BUP microdose induction protocol (without stopping full agonists).~Day 1: participants will receive buprenorphine (Belbuca) 225 mcg mg every 12 hours Day 2: participants will receive buprenorphine (Belbuca) 450 mcg every 8 hours Day 3: participants will receive buprenorphine-naloxone 2-0.5 mg every 8 hours Day 4: participants will receive buprenorphine-naloxone 4-1 mg every 8 hours Day 5: participants will receive buprenorphine-naloxone 8-2 mg every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: 2-day standard BUP induction protocol (with stopping full agonists) Day 1: hold all opioids Day 2: buprenorphine-naloxone 2-0.5 mg every 6 hours Day 3: buprenorphine-naloxone 8-2 mg every 12 hours
Study: NCT05437094

Intervention type: DRUG
Group type: OTHER
Intervention: CRD-740
Description: CRD-740

Intervention type: DRUG
Group type: OTHER
Intervention: CRD-740
Description: CRD-740

Intervention type: DRUG
Group type: OTHER
Intervention: Itraconazole
Description: Itraconazole
Study: NCT05118204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linkage to outpatient BUP treatment
Description: Participants will be given an expedited appointment (within 2 weeks) to continue BUP treatment at a Montefiore community health center

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Linkage to outpatient BUP treatment
Description: Participants will be given an expedited appointment (within 2 weeks) to continue BUP treatment at a Montefiore community health center
Study: NCT06401538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMB-101
Description: BMB-101 liquid administered orally twice a day for 3 months
Study: NCT05509712

Intervention type: BEHAVIORAL
Intervention: Focus Groups to Refine MobileMen App Content
Description: Participants are shown a clickable wireframe of the proposed new app features, including competition, animated badges, leaderboard, and incentives. Focus group members discuss perceptions, ease of use, and interest in the app design/features and identified additional or unnecessary features for adopting and maintaining physical activity (PA).
Study: NCT06382688

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NAD+ (nicotinamide adenine dinucleotide) IV
Description: NAD+ enables cells to generate cellular energy from the food that one eats

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen® (nicotinamide riboside) IV
Description: NR is a unique member of the vitamin B3 family. Cells can use NR to create nicotinamide adenine dinucleotide (NAD+), which is an essential molecule found in every living cell. Patients in this arm received an IV administration.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Niagen® (nicotinamide riboside) oral
Description: NR is a unique member of the vitamin B3 family. Cells can use NR to create nicotinamide adenine dinucleotide (NAD+), which is an essential molecule found in every living cell. Patients in this arm received an oral administration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: These individuals received a saline IV
Study: NCT05863429

Intervention type: BIOLOGICAL
Intervention: Taking biological samples (blood) and keeping records with phone calls
Description: Within the scope of the study, no intervention will be made to the participants. According to the vaccination program implemented in Turkey, subjects who apply to the study centers for TURKOVAC vaccine will be invited to the study.

Intervention type: BIOLOGICAL
Intervention: Taking biological samples (blood) and keeping records with phone calls
Description: Within the scope of the study, no intervention will be made to the participants. According to the vaccination program implemented in Turkey, subjects who apply to the study centers for TURKOVAC vaccine will be invited to the study.

Intervention type: BIOLOGICAL
Intervention: Taking biological samples (blood) and keeping records with phone calls
Description: Within the scope of the study, no intervention will be made to the participants. According to the vaccination program implemented in Turkey, subjects who apply to the study centers for TURKOVAC vaccine will be invited to the study.
Study: NCT05165394

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-1065846
Description: Tablets for oral administration
Study: NCT04781777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: sonar guided insulin combined with dexamethasone and local anesthetics
Study: NCT06415851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody
Description: This study is a single-arm intervention study. All subjects in this study will be treated with this study protocol, that is, after mFOLFOX6 protocol and bevacizumab induction therapy, combined with slulimumab treatment.
Study: NCT05599919

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitric Oxide
Description: The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
Study: NCT06110975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deprescribing-intervention
Description: The clinical guideline on Deprescribing drugs for OAB in The North Denmark Region serves as the basis for the intervention. The guideline provides recommended procedures for the deprescribing process. The guideline offers procedures for the deprescribing process and includes a deprescribing algorithm and a symptom questionnaire designed to evaluate the impact of medications utilized in the treatment of OAB.
Study: NCT05287542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion
Description: The intervention group will receive four weekly 60 min. sessions with hypnosis treatment including induction followed by hypnotic suggestion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: The active control group will receive four weekly 60 min. sessions of induction and mindfulness-based instructions.
Study: NCT05130944

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Entre Nosotras
Description: A series of five 2-hour group sessions that are administered weekly by two trained female peer facilitators, who are selected by HIAS outreach workers and/or community leaders. The content of the sessions is based on the principles of Psychological First Aid and the Participatory Action Cycle, which is intended to generate community-led problem solving around priority issues affecting their wellbeing.~Entre Nosotras is a community- and strengths-based intervention designed to mobilize social support, strengthen community connectedness, and stimulate collective action to promote the safety and wellbeing of women.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Entre Nosotras
Description: A series of five 2-hour group sessions that are administered weekly by two trained female peer facilitators, who are selected by HIAS outreach workers and/or community leaders. The content of the sessions is based on the principles of Psychological First Aid and the Participatory Action Cycle, which is intended to generate community-led problem solving around priority issues affecting their wellbeing.~Entre Nosotras is a community- and strengths-based intervention designed to mobilize social support, strengthen community connectedness, and stimulate collective action to promote the safety and wellbeing of women.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doing What Matters in Times of Stress
Description: The stress management components are derived from the World Health Organization Doing What Matters in Times of Stress illustrated guide for coping with adversity (World Health Organization, 2020). The illustrated guide and accompanying audio files are publicly available: https://www.who.int/publications/i/item/9789240003927. During five sessions, the intervention involves 15-20 minute exercises covering a range of stress management and coping skills.
Study: NCT04696497

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound
Description: Ultrasound measurements of muscle thickness, using a linear probe (high frequency) on four muscle groups:~* Shoulder Side muscular compartment~* Anterior Arm muscular compartment~* Anterior thigh muscular compartment~* Antero-lateral leg muscular compartment

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dynamometric muscular assessment
Description: The principle of electronic dynamometry is to measure an isometric force. To carry out these measurements, the examiner will stand on the side who has to be tested by exerting a pressure diametrically opposite to the patient's movement, thus preventing him/her from carrying out the movement. The patient will perform 3 tests for each movement, the best value will be collected by the examiner.~The reference position is :~Patient elbowed to the body bent at 90°, with trunk inclination at 30° in the resuscitation bed, lower limbs flat.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Manual muscular Assessment (MRC-SS)
Description: Following the same positions as for the dynamometer, the examiner will evaluate the 12 motor functions according to the following 60-point rating. With the maximum quote of 5 point representing normal strength and 0 point the total absence of any muscular contraction
Study: NCT06461429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: Antibiotic. Standard of care. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin and Erythromycin
Description: Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
Study: NCT05509712

Intervention type: BEHAVIORAL
Intervention: Beta testing of MobileMen App Prototype
Description: Project staff present the clickable wireframe prototype and have men navigate and test features using a structured script. Staff track participant responses in notes, as well as through both recording via a side profile and the device screen. At the conclusion of the session, participants complete surveys measuring satisfaction, helpfulness, and usability.
Study: NCT06461429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine citrate: Low dose
Description: Lower dose caffeine: 20mg/kg load and 10mg/kg/day maintenance. Standard of care. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
Study: NCT05235854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection of corticosteroids (Diprostène®)
Description: Diprostène® will be injected into the knee. This is a 1 ml syringe of Betamethasone 2 mg, suspension for injection in pre-filled syringe.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection of corticosteroids (Diprostène®)
Description: Diprostène® will be injected into the knee. This is a 1 ml syringe of Betamethasone 2 mg, suspension for injection in pre-filled syringe.
Study: NCT04222023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIG)
Description: Experimental group: administration of a single dose of IVIG at:~* Day 10+/- 4 days~* Day 41 +/- 7 days~* Day 62 +/- 7 days The dose of IVIG is defined according the donor BKV genotype: genotype I: 0.4 g/Kg/day; genotype II and IV: 1g/kg/day.
Study: NCT06626165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirikizumab
Description: Mirikizmgab will be administered based on the result of Geboes score Grade ≥ 3.2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab
Description: Vedolizmab will be administered based on the result of Geboes score Grade 3.1.
Study: NCT05655195

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GENUS device (Active Settings)
Description: Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 60 minutes daily for 6 months.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GENUS device (sham settings)
Description: Participants in the control group will use the GENUS devices configured to the sham settings for 60 minutes daily for 6 months.
Study: NCT04476485

Intervention type: OTHER
Intervention: endocrine therapy
Description: If the expression of sj-subway in the surgical wax block is eligible, it is recommended but not mandatory that patients follow the guidelines to choose the appropriate extended endocrine therapy. 1. For postmenopausal patients: Extend treatment with aromatase inhibitors 10 years: letrozole or anastrozole or exemestane. 2. For premenopausal patients: An initial 5 years tamoxifen treatment followed by additional 5 years extended tamoxifen treatment. Postmenopausals are treated with aromatase inhibitors 5 years. 3. For patients have completed ovarian function suppression plus initial 5-year aromatase inhibitor treatment: Menopausals: Aromatase inhibitors; Non-menopausals: 5 years of tamoxifen treatment or ovarian function suppression plus 5 years of aromatase inhibitor treatment. 4. For patients have completed ovarian function suppression plus initial 5-year tamoxifen treatment: Menopausals: Aromatase inhibitors for additional 5 years; Non-menopausals: Tamoxifen for additional 5 years.
Study: NCT05511480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interference through learning of a competing motor skill.
Description: Interference through the learning of a competing motor skill.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interference through learning of a competing motor skill.
Description: Interference through the learning of a competing motor skill.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interference through learning of a competing motor skill.
Description: Interference through the learning of a competing motor skill.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No interference
Description: No interference through the continuation of learning same motor skill
Study: NCT06200363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered intravenously on D1, 4, 8, 11, 15, 18 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib will be administered orally once daily for the first 21 days of each 28-day cycle according to NCCN and CSCO guidance.
Study: NCT06409377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex 200 MCG in 2 ML Injection
Description: Patients received dexmedetomidine (1.5 μg/kg) as single injection over 10 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: C group:
Description: Patients received propofol (2 mg/kg), fentanyl (1 μg/kg), and atracurium (0.5 mg/kg).
Study: NCT05049291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telehealth advance care planning
Description: An education information sheet containing prognosis and outcomes of acute care and intensive treatments